1. Introduction {#s0005}
===============

Nausea and vomiting are the most commonly occurring symptoms in majority of pathophysiological conditions such as motion, cancer, pregnancy, and postoperative conditions. Nausea refers to feeling of impending vomiting. Vomiting refers to forceful expulsion of contents of the stomach and the proximal small intestine ([@b0110]).

Antiemetic drugs are used to prevent or suppress vomiting. They act by blocking several receptors located in vomiting centres such as H~1~ histaminic, dopamine D~2~, 5-HT~3~ receptor, muscarinic, and neurokinin1(NK~1~) receptor. Drugs such as Anticholinergics, H~1~-antihistamines, Neuroleptics, 5-HT~3~ antagonists act by penetrating blood brain barrier which leads to sedation. Prokinetic drugs such as metoclopramide and domperidone maleate act as dopamine D~2~ blockers. Their antiemetic activity is due to antagonism of D~2~ receptors in Chemoreceptor Trigger Zone (CTZ) which is located outside of the blood brain barrier so they do not cause side effects related to brain and hence do not cause disturbance in regular activities such as driving, and office work. It is reported that metoclopramide has more side effects as compared to Domperidone maleate ([@b0135]).

Domperidone Maleate (DM) has very low oral bioavailability (15%) owing to its extensive metabolism in liver and gut wall ([@b0135]). It is available in the form of tablets, capsules, suspensions, injections, sustained release capsules, etc. But these formulations have several disadvantages such as difficulty in swallowing tablets or capsules which also requires water. Besides these, suspension does not possess pleasant taste and dose accuracy. Patients suffering from trypanophobia experience difficulty in medication by needle. In addition, drug if given by oral route, undergoes first pass metabolism that decreases bioavailability of DM. Formulations of DM investigated by various researchers are coevaporates ([@b0095]), fast dissolving tablet ([@b0015]), orodispersible tablet ([@b0065]), etc.

Chewing gum is a pleasure that almost everyone enjoys. Chewing gum usually consists of a gum core, which may or may not be coated. Medicated chewing gums are defined by the European Pharmacopoeia and the guidelines for pharmaceutical dosage forms issued in 1991 by the Committee for Medicinal Products for Human Use (CPMP) as 'solid single dose preparations with a base consisting mainly of gum that are intended to be chewed but not to be swallowed, providing a slow steady release of the medicine contained' ([@b0055]). Chewing gum has also being exploited for the drug delivery and many times referred as mobile drug delivery system ([@b0060]). Medicated chewing gum (MCG) gives local (treatment of oral disease) as well as systemic action (buccal absorption or by swallowing saliva). MCG helps to increase patient compliance by fast onset of action and by improved bioavailability of drug as some amount of drug is absorbed through the buccal mucosa. It can also be administered without water ([@b0070], [@b0025], [@b0030]). MCG has been exploited for various drugs such as cetirizine ([@b0125], [@b0130]), dextromethorphan hydrobromide ([@b0130]), dimenhydrinate hydrochloride ([@b0080]), nicotine ([@b0085], [@b0035]), antacids ([@b0155]), miconazole ([@b0105]), aspirin ([@b0150]), caffeine ([@b0140]), antimicrobial decapeptide ([@b0050]), ondansetron hydrochloride ([@b0090]), and nystatin ([@b0010]).

The aim of present research work was to formulate medicated chewing gum of DM to fasten the onset of action and to improve the bioavailability so as to get the quick relief from nausea and vomiting with greater patient compliance.

2. Methods {#s0010}
==========

2.1. Materials {#s0015}
--------------

DM was received as gift sample from Vasudha Pharma Chemical Limited (Hyderabad, India). Health In Gum® (HIG PWD 02) was received as gift sample from Cafosa (Barcelona, Spain). All other ingredients and solvents used were of analytical or pharmaceutical grade.

2.2. Drug excipients compatibility study {#s0020}
----------------------------------------

### 2.2.1. Fourier Transform Infrared Study (FTIR) {#s0025}

The drug-excipient compatibility study was carried out by FTIR. FTIR spectra of the (a) pure drug, (b) gum base and (c) mixture of drug:excipients (1:99) were recorded. The samples were prepared by weighing and homogenously dispersing with dried KBr in a mortar and pestle, and compressing the powder under vacuum with a compression force using round flat face punch for three minutes to produce a pellet compacts. The sample was placed in the IR light path using a FTIR Instrument (NICHOLET 6700, Thermo Scientific, USA). Spectra were recorded in the wavelength region of 4000--400 cm^−1^. The peaks were observed for any types of interaction between the drug and excipients ([@b0045]).

2.3. Formulation development of MCG {#s0030}
-----------------------------------

The technique of screening of one excipient at a time was adopted. The whole process of the formulation development is given in [Fig. 1](#f0005){ref-type="fig"}.

2.4. Pre-compression study {#s0035}
--------------------------

Flow properties of gum base and drug: excipient mixtures were determined by measurement of angle of repose, bulk density, tapped density, compressibility index (CI) and hausner's ratio.

2.5. Preparation of medicated chewing gum {#s0040}
-----------------------------------------

Medicated chewing gums were prepared by direct compression method. In this method, the flavour was added in accurately weighed DM with continuous mixing in a mortar for 15 min. Flavoured drug was screened through 30\# sieve (0.600 mm) followed by addition of accurately weighed and 30\# pre-sifted gum base, anti-adherent and sweeteners and blended for 10 min. 30\# pre-sifted lubricant was precisely added and blended for 10 min. Finally, the prepared blend of formulation was compressed on a tablet compression machine (Rimek Mini Press-II, Karnavati Engineering) ([@b0115]).

2.6. Screening of excipients by human volunteers {#s0045}
------------------------------------------------

MCGs were evaluated for several organoleptic properties such as chewability, flavour lasting time, sweetness, and softness in a panel of healthy human volunteers (*n* = 6). The permission for conducting these studies was obtained from Institutional Ethics Committee-Human Research. \[Protocol No. RPCP/IECHR/PG/2012-2013/R11.02\].

Volunteers those who signed the informed consent form ([Annexure I](#s0230){ref-type="sec"}) were selected. Before starting the experiment, all volunteers were instructed to rinse their mouth thoroughly and were asked about any adverse effect towards DM. They reported the responses of the tests in questionnaire form ([Annexure II](#s0230){ref-type="sec"}). Selection and optimization of an individual excipient was performed by screening each excipient with respect to desired criteria. The prepared formulation composition is shown in [Table 1](#t0005){ref-type="table"}.

2.7. Optimization of chewable mass {#s0050}
----------------------------------

To obtain good chewability of dosage form, the MCGs were formulated in different sizes (Batch M1--M3) and evaluated by healthy human volunteers. They were allowed to chew MCG of different sizes and MCG with good chewability was selected based on scale of chewability as mentioned in [Table 2](#t0010){ref-type="table"}. The optimized mass was kept constant for further studies.

2.8. Screening of flavours {#s0055}
--------------------------

To formulate MCGs with good flavour lasting time, different flavours such as chocolate, cherry, peppermint oil, water-melon, orange were screened. MCGs containing different flavours were prepared (Batch M4--M8). MCGs were allowed to chew by healthy human volunteers up to 5 min and they were asked to report the flavour lasting time. MCG which had longer flavour lasting time was selected for further studies.

2.9. Screening of sweeteners {#s0060}
----------------------------

Sweeteners are the important part of the MCGs. Drug has moderate bitter taste and so it needs to be masked to enhance patient compliance. To mask the bitter taste of DM, different sweeteners such as mannitol, acesulfame, aspartame, glycyrrhiza, mono-ammonium glycyrrhizinate (MAG) (Batch M9--M28) were screened. Accurately weighed sweeteners were taken and MCGs were prepared by direct compression method. Taste acceptability was measured by a panel of volunteers (*n* = 6). Each volunteer was asked to hold MCG for 5--10 s, then spat out and to report taste rank as shown in [Table 2](#t0010){ref-type="table"}. Formulation with excellent taste masking (taste rank: 4) was selected for further studies ([@b0045]).

2.10. Screening of softening agents {#s0065}
-----------------------------------

To obtain good softness in MCG, screening of different softening agents such as glycerol, stearic acid, soya lecithin was performed. Accurately weighed softener was taken (Batch M29--M35) and MCGs were evaluated by six healthy human volunteers based on the scale of softness as shown in [Table 2](#t0010){ref-type="table"}.

2.11. Screening of lubricants {#s0070}
-----------------------------

Different lubricants such as Magnesium Stearate and Acryflow™ were selected by taking different concentrations and by measuring flow characteristics of the drug: excipient mixture. MCGs containing different concentrations of lubricant (Batch M36--M41) were observed for smooth ejection during compression in tablet punching machine. MCG with less concentration of lubricant and smooth ejection was selected for further studies.

2.12. Screening of anti-adherents {#s0075}
---------------------------------

Different concentrations of anti-adherent (talc) were screened. MCGs containing different concentrations of anti-adherent (Batch M42--M46) were observed for smooth ejection and stickiness to die or punch of tablet punching machine. MCGs with less concentration of anti-adherent and less/no stickiness were selected for formulation of MCG.

2.13. Post-compression studies {#s0080}
------------------------------

Appearance, size, shape, thickness and diameter of MCG were observed by taking ten medicated chewing gum randomly. Thickness and diameter were measured by digital vernier caliper and appearance, size, shapes of the medicated chewing gums were evaluated visually. The hardness of six medicated chewing gums was determined by diametrical compression using a Monsanto hardness tester and the average value was calculated and expressed as kg/cm^2^. Weight variation test was performed by selection of twenty medicated chewing gum randomly. They were weighed individually and the average weight was calculated from total weight. Then percentage deviation from the average was calculated ([@b0055]).$$\text{Percentage\ weight\ variation} = (\text{Weight\ of\ individual\ MCG}/\text{Average\ weight\ of}\ 20\ \text{MCGs}) \ast 100$$

2.14. Friability {#s0085}
----------------

Ten MCGs were randomly taken and carefully de-dusted prior to weighing. They were weighed and placed in the Roche Friabilator (EF-2, Electrolab®) which was rotated for 100 revolutions at 25 rpm. The medicated chewing gums were then de-dusted and reweighed. A maximum loss of mass (obtained from a single test or from the mean of three tests) was calculated in percentage ([@b0025]).

2.15. Content uniformity test {#s0090}
-----------------------------

The individual contents of active substance of 10 dosage units which were taken randomly were determined. The 10 dosage forms were crushed in mortar and powder equivalent to 10 mg of DM was taken. The powder was dissolved in 100 ml of conical flask containing phosphate buffer pH 6.8. The absorbance measurements of these solutions were taken by UV--Visible spectrophotometer at 284 nm. The formulation complies with the test if the individual content is between 85% and 115% of the average content ([@b0055]).

2.16. % Loss on drying {#s0095}
----------------------

\% Loss on drying was measured in IR moisture balance instrument (MA 45 model, Sartorius, India) for 4 min. The optimized MCG (M46 batch) was placed in aluminium disc in moisture balance. The temperature was set at 105 °C and the % loss on drying (% LOD) was determined ([@b0145]).

2.17. Evaluation of optimized batch {#s0100}
-----------------------------------

### 2.17.1. Statistical analysis of MCG quality {#s0105}

For product quality assessment, a sensory panel of 6 human volunteers had been formed. They had given two formulations for chewing (a) M46 (final optimized MCG) (b) M4 (MCG containing only gum base with DM and flavour) to evaluate organoleptic properties such as Taste, Consistency, Softness, Flavour lasting time. Volunteers had given score individually by chewing both the products. After assessment, filled forms with score (*x* out of 4) were received from volunteers. The average score was calculated for each of the four different qualities. Paired *t*-test was applied to test whether there is any significant improvement in product quality after excipient treatment or not ([@b0025]).

### 2.17.2. Scanning electron microscopy (SEM) {#s0110}

Morphological surface characteristic of prepared MCG was analysed using scanning electron microscope. The medicated chewing gums of M46 (optimized batch) and M34 (MCG without lubricant) were fixed on aluminium stubs with double sided tape and examined in Jeol scanning electron microscope 5610 LV using an accelerating voltage of 2.0--30 kV, at magnification of 250×, 500× and 1000× ([@b0020]).

### 2.17.3. Texture analysis by instrument {#s0115}

Instrumental texture analysis is mainly concerned with the evaluation of mechanical characteristics where a material is subjected to a controlled force from which a deformation curve of its response is generated. Texture property of directly compressed MCG was evaluated using Brookfield® QTS-25 texture analyser. It was recommended to use a compression probe with surface area of 4 mm^2^. During evaluation, a constant force was applied on the surface of self-supporting MCG and upon fracture it was withdrawn. Deformation curve was recorded and interpreted. Peak load required for deformation of MCG was determined ([@b0025]).

### 2.17.4. In-vivo drug release study {#s0120}

The in vivo drug release of DM from MCG during mastication was studied by recruiting a panel of six numbers of volunteers and scheduled chew-out studies for determination of % drug release from MCG. Each person was allowed to chew one sample of the DM MCG for a particular time period, i.e. 0.5, 1, 2, 5, 10, and 15 min. After chewing, chewed out gum samples were collected from volunteers, stretched out up to maximum and cut into small pieces and dispersed in a 100 ml volumetric flask containing phosphate buffer pH 6.8, which was then sonicated for 10 min with heating. The sonicated sample was filtered and analysed by a UV spectrophotometer at 284 nm to determine the residual drug content present in MCG. The "amount of drug released during mastication" was calculated by subtracting the "amount of the residual active ingredient" presents in the gum after chewing from "the total content" ([@b0025], [@b0100]).$$\text{Amount\ of\ drug\ released\ during\ mastication} = \text{Total\ content} - \text{Amount\ of\ the\ drug\ in\ residual\ active\ ingredient.}$$

### 2.17.5. *Ex-vivo* buccal permeation study {#s0125}

Buccal mucosa was obtained from the approved slaughter house. The permission for conducting this study was obtained from Institutional Animal Ethics Committee (IAEC). \[Protocol No: RPCP/IAEC/2012-2013/MPH-PT-26\]. Goat buccal mucosa was cleaned and placed between a donor compartment and a receiver compartment of the Franz diffusion cell. To simulate oral conditions, phosphate buffer of salivary pH (pH 6.8) was filled in the donor compartment and phosphate buffer of blood pH (pH 7.4) was filled in the receiver compartment. The average amount of DM, which was released from optimized formulation after 15 min of chewing, was placed in the donor compartment. It was allowed to permeate through buccal mucosa for 30 min. At 5 min interval the sample was collected from the receiver compartment and analysed by the UV-spectrophotometer at 284 nm, to determine the total content of DM permeated through buccal mucosa. The study was performed in triplicate ([@b0025]).

3. Result and discussion {#s0130}
========================

3.1. Drug excipients compatibility study {#s0135}
----------------------------------------

The FTIR spectra as shown in [Fig. 2](#f0010){ref-type="fig"} indicated that there were no changes in standard wave number of the drug and excipients. So, there is no interaction between pure drug, pure gum base and excipients. It indicates that drug and excipients are compatible.

3.2. Pre-compression studies {#s0140}
----------------------------

The results of pre-compression studies are shown in [Table 3](#t0015){ref-type="table"}. Angle of repose of gum base and drug: excipients mixture was found to be 30.70 ± 1.02 and 29.49 ± 2.41, respectively. Angle of repose less than or equal to 30 indicates excellent flow property so it was concluded that the gum base and drug:excipients mixture had excellent flow property. Compressibility index for gum base and drug: excipients mixture was found to be 9.20 ± 0.72% and 9.46 ± 0.17%, respectively, which indicates excellent compressibility of gum base and mixture. Compressibility is the parameter used to determine compression efficiency of powder during compression. Compressibility index less than 10% indicates excellent compressibility. Hausner's ratio for gum base and mixture was found to be 1.09 ± 0.011 and 1.10 ± 0.02, respectively, which represents good flowability because Hausner's ratio between 1.00 and 1.11 represents excellent flowability. Thus, from the results it was indicated that the gum base and mixture of drug and excipients showed excellent flow property and compressibility which is favourable for direct compression.

3.3. Formulation and development of medicated chewing gum {#s0145}
---------------------------------------------------------

The details of all the batches are given in [Table 1](#t0005){ref-type="table"}.

3.4. Optimization of chewable mass {#s0150}
----------------------------------

The batches from M1 to M3 were formulated to optimize chewable mass from the response of healthy human volunteers (*n* = 6) and it was found that MCG of Batches M1 (500 mg) and M2 (600 mg) showed poor chewability due to less chewable mass which was not favourable for MCG. The batch M3 (1000 mg) showed very good chewability due to proper chewable mass. So, the size of medicated chewing gum was fixed as 1000 mg for further formulation.

3.5. Screening of flavours {#s0155}
--------------------------

The batches of MCGs containing different flavours were formulated (M4--M8). The responses were observed in healthy human volunteers (*n* = 6) and it was observed that the flavour lasting time for M5 (orange) and M7 (water melon) was about 1 min so imparted bitter taste during mastication. M6 (peppermint oil) had flavour lasting time up to 2 min. The M8 (chocolate) has good flavour lasting time up to 4 min but that was lower as compared to cherry flavour. The highest flavour lasting time observed with M4 (cherry) was up to 5 min. So, M4 batch containing cherry as flavour was selected.

3.6. Screening of sweeteners {#s0160}
----------------------------

Sweeteners are the important part of the MCGs. Drug has moderate bitter taste and so, it needs to be reduced or to be masked to enhance patient compliance. The batches M9--M28 were formulated using different concentration of sweeteners. The responses were observed in healthy human volunteers (*n* = 6). Based on the response it was concluded that batch M4 (without sweetener) has bitter taste which is rated 0 as per the taste rank shown in [Table 2](#t0010){ref-type="table"}. In the batches M9--M13 containing different sweeteners, it was observed that these batches had moderate bitterness. So, it was decided to formulate MCG with the blend of sweeteners so as to get the complete taste masking.

In the MCGs containing different Blend of Sweeteners, it was found that the batch M21 containing highest amount of MAG: Aspartame (100 mg: 60 mg), masked the bitter taste but it had some bitter after taste that may be due to aspartame or MAG. To optimize the concentration of MAG and aspartame, further batches (M22--M28) were formulated. Batch M22 containing 50 mg of aspartame showed complete taste masking so it was optimized for further formulation. To test the effectiveness of MAG on taste masking the amount of MAG was decreased further. Monoammonium glycyrrhizinate (MAG) can be used as sweetness potentiator. The MCGs of M27 (30 mg of MAG) showed proper taste masking. It was concluded that batch M27 at amount (30 mg MAG: 50 mg Aspartame) had excellent taste masking, so, this ratio was selected for further formulation.

3.7. Screening of softening agents {#s0165}
----------------------------------

It was observed that batch M29 containing glycerol had good softening property but it affects the flow properties because of viscous nature. The batch M30 containing stearic acid was very hard to chew and had grittiness during mastication while the batch M31 containing soya lecithin provided very good softness and consistency to the MCG, so, it was selected as softening agent for further study.

Soya lecithin also helps to suppress bitter taste of DM ([@b0120]). Further, it was found that the concentration of softener may affect the release of drug from MCG. So, concentration of softener was optimized based on drug release. The batches M31--M35 containing different concentration of soya lecithin (1--3% w/w) was formulated and drug release study was performed in healthy human volunteers**.** It was found that M34 (2% soya lecithin) showed highest drug release. The MCGs containing soya lecithin more than 2% were split into pieces during chewing which showed poor acceptability. So, 2% soya lecithin concentration was optimized and kept constant for further formulation.

3.8. Screening of lubricants {#s0170}
----------------------------

The batches (M36--M41) containing different concentrations (0.5--3% w/w) of lubricant (Acryflow™) were prepared. Magnesium stearate is most widely used as lubricant but it was found that it retards dissolution of some APIs and the magnesium salt sometimes shows incompatibility with APIs ([@b0005]). Acryflow™ is poly-hydroxy stearate derivatives and it has nonreactive functional group, so, it does not have incompatibility with APIs ([@b0040]). The selection of lubricant was performed based on its flow properties and the results showed that the angle of repose ranges from 31 to 36 which indicates good flowability. Hausner's ratio was found in the range 1.071--1.081 which indicates excellent flowability. The compressibility index was found to be 6.66 which indicates excellent compressibility. Acryflow™ in the concentration of 1% w/w i.e. 10 mg (Batch M37) was selected as lubricant as it showed good flow properties, excellent compressibility and smooth ejection from tablet punching machine.

3.9. Screening of anti-adherent {#s0175}
-------------------------------

The batches M42--M46 containing different concentration of talc were prepared. The amount of talc selected based on stickiness of MCGs to punch. It was found that in batch M46, MCG did not stick to punch and was easy to eject out. So, batch M46 containing 50 mg talc was selected for final formulation.

3.10. Post-compression study {#s0180}
----------------------------

The results of the post-compression studies are shown in [Table 4](#t0020){ref-type="table"}. From the visual inspection by healthy volunteers, it was found that the appearance, size, shape of optimized MCG were aesthetic. The mean thickness (*n* = 10) and mean diameter (*n* = 10) were uniform with value ranging between 6.662--6.681 mm and 12.46--12.52 mm^2^, respectively. The average weight of compresses MCG formulations was within the range of 0.998--1.008 mg. So, all compressed MCGs passed weight variation test for compressed tablets as per European Pharmacopoeia. The weight of all the MCGs was found to be uniform with low standard deviation values. The measured hardness of tablets ranged between 2 and 3 kg/cm^2^ which ensures good handling characteristics of MCG. The % friability was less than 1% in all the formulations ensuring that the MCGs were mechanically stable. The percentage drug content of the all the MCGs ranged within 98.25% to 105.67%, which was within acceptable limits indicating dose uniformity in each MCG. The mean % of loss on drying of optimized MCGs was found to be in range of 0.40--0.41%, which is within acceptable limits indicating higher stability of MCGs.

3.11. Evaluation of optimized batch {#s0185}
-----------------------------------

### 3.11.1. Statistical Analysis of MCG quality {#s0190}

The statistical analysis of MCG (a) M46 (b) M4 was performed for its quality evaluation. The Organoleptic properties such as taste, consistency, softness, flavour lasting time were evaluated from the response of healthy human volunteers (*n* = 6). The Comparison of score obtained from responses was represented in [Fig. 3](#f0015){ref-type="fig"}. The average score was calculated for each of four different qualities and the results of which are as shown in [Table 5](#t0025){ref-type="table"}.

Paired *t*-test was applied to test any significant improvement in product quality after excipients treatment and the results for which are as shown in [Table 6](#t0030){ref-type="table"}. It was concluded that for all quality parameters, *t*~cal~ \> *t*~tab~ so there is a significant improvement in product quality after treatment with excipients. It was confirmed that there is a significant improvement in the product taste, product consistency, product softness and total flavour lasting time after incorporation of appropriate excipients in an optimum amount in M45 (final optimized MCG formulation).

### 3.11.2. Scanning Electron Microscopy (SEM) {#s0195}

The SEM images ([Fig. 4](#f0020){ref-type="fig"}) clearly indicate that optimized formulation has smoother surface as compared to MCG without lubricants. So, it was concluded that M45 can increase patient acceptance due to aesthetic surface property.

### 3.11.3. Texture analysis study {#s0200}

It was found that peak load required for deformation of medicated chewing gum was 11062 ± 1225.6 g with 4 mm probe. The MCG initially crumbles and then comes together to form a chewable gum mass. The crumbling of the MCG allows DM to be released and provides a faster release as compared to conventional gums, which remain intact during the process ([@b0075]). The results of texture analysis study are given in [Table 7](#t0035){ref-type="table"} and [Fig. 5](#f0025){ref-type="fig"}.

### 3.11.4. In-vivo drug release study {#s0205}

The results of in vivo drug release at different time intervals are as shown in [Fig. 6](#f0030){ref-type="fig"}. Individual % DM release is mentioned in [Table 8](#t0040){ref-type="table"} and [Fig. 7](#f0035){ref-type="fig"}. From the results, it was observed that drug release after 15 min of chewing was 97.15%. Initially, due to the breaking of the MCG, the release of the drug was very fast as it was observed that almost 80% of the drug was released within 2 min. This is a good indication as the fast release of drug resulted in the fast absorption and ultimately the fast onset of action. The radar plot ([Fig. 8](#f0040){ref-type="fig"}) showed the % drug release from MCG at specific time (0.5, 1, 2, 5, 10 and 15 min) in healthy human volunteers (A--F).

### 3.11.5. Ex-vivo buccal permeation study {#s0210}

The results of buccal permeation study of DM performed on goat buccal mucosa are given in [Fig. 9](#f0045){ref-type="fig"}. From the results, it was observed that the amount of drug permeated through buccal mucosa was 1.09 mg (11.27%) in 15 min. It is hypothesized from the results of the buccal permeation that the significant amount of the drug may permeated (absorbed) through the buccal route, which may increase bioavailability of DM and decrease onset time.

4. Conclusion {#s0215}
=============

The study concludes the possibility of the formulation of the directly compressible MCG of DM using HealthinGum® (gum base) with the improved taste by using combination of the sweeteners. The first pass metabolism associated with DM can also be solved by the MCG, as the main site of absorption is buccal. The MCG formulation of DM is a novel approach for the treatment of nausea and vomiting associated with motion sickness and other pathophysiological conditions. MCG can increase patient compliance and patient acceptance as well as increase the bioavailability of DM as it showed significant permeation through buccal mucosa. However, clinical pharmacokinetic data are needed to prove it further.
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###### 

Selection and optimization of DM Medicated chewing gum formulation (M1--M46).

  -------------------- --------------- ------------ --------- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- -----
  Category             Ingredients     Batch code                                                                         
                                                                                                                          
  M1                   M2              M3           M4        M5    M6    M7    M8    M9    M10   M11   M12   M13         
                                                                                                                          
  Drug                 DM              10           10        10    10    10    10    10    10    10    10    10    10    10
  Gum base             Health in gum   480          580       980   980   980   980   980   980   880   973   880   920   880
  Flavour              Cherry          --           --        --    10    --    --    --    --    10    10    10    10    10
  Orange               --              --           --        --    10    --    --    --    --    --    --    --    --    
  Peppermint oil       --              --           --        --    --    10    --    --    --    --    --    --    --    
  Water melon          --              --           --        --    --    --    10    --    --    --    --    --    --    
  Chocolate            --              --           --        --    --    --    --    10    --    --    --    --    --    
  Sweetener            Mannitol        --           --        --    --    --    --    --    --    100   --    --    --    --
  Acesulfame           --              --           --        --    --    --    --    --    --    7     --    --    --    
  MAG                  --              --           --        --    --    --    --    --    --    --    100   --    --    
  Aspartame            --              --           --        --    --    --    --    --    --    --    --    60    --    
  Glycyrrhiza glabra   --              --           --        --    --    --    --    --    --    --    --    --    100   
                                                                                                                          
  Total weight         500 mg          600 mg       1000 mg                                                               
  -------------------- --------------- ------------ --------- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- -----

  -------------------- --------------- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- -----
  Category             Ingredients     M14   M15   M16   M17   M18   M19   M20   M21   M22   M23   M24   M25   M26   M27   M28
                                                                                                                           
  Drug                 DM              10    10    10    10    10    10    10    10    10    10    10    10    10    10    10
  Gum base             Health in gum   963   953   943   933   923   913   820   820   830   840   850   870   890   900   910
  Flavour              Cherry          10    10    10    10    10    10    10    10    10    10    10    10    10    10    10
  Sweetener            Mannitol        --    --    --    --    --    --    --    --                                        
  Acesulfame           7               7     7     7     7     7     7     --                                              
  MAG                  --              --    --    --    --    --    100   100   100   100   80    60    40    30    20    
  Aspartame            10              20    30    40    50    60    --    60    50    40    50    50    50    50    50    
  Glycyrrhiza glabra   --              --    --    --    --    --    --    --          --    --    --    --    --    --    
                                                                                                                           
  Total weight         1000 mg                                                                                             
  -------------------- --------------- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- -----

  --------------- --------------- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- -----
  Category        Ingredients     M29   M30   M31   M32   M33   M34   M35   M36   M37   M38   M39   M40   M41   M42   M43   M44   M45   M46
                                                                                                                                        
  Drug            DM              10    10    10    10    10    10    10    10    10    10    10    10    10    10    10    10    10    10
  Gum base        Health in gum   800   850   850   860   870   880   890   875   870   865   860   855   850   860   850   840   830   820
  Flavour         Cherry          10    10    10    10    10    10    10    10    10    10    10    10    10    10    10    10    10    10
  Sweetener       MAG             30    30    30    30    30    30    30    30    30    30    30    30    30    30    30    30    30    30
  Aspartame       50              50    50    50    50    50    50    50    50    50    50    50    50    50    50    50    50    50    
  Softener        Glycerol        100   --    --    --    --    --    --    --    --    --    --    --    --    --    --    --    --    
                  Stearic acid    --    50    --    --    --    --    --    --    --    --    --    --    --    --    --    --    --    --
                  Soyalecithin    --    --    50    40    30    20    10    20    20    20    20    20    20    20    20    20    20    20
  Lubricant       Acryflow        --    --    --    --    --    --    --    5     10    15    20    25    30    10    10    10    10    10
  Anti-adherent   Talc            --    --    --    --    --    --    --    --    --    --    --    --    --    10    20    30    40    50
                                                                                                                                        
  Total weight    1000 mg                                                                                                               
  --------------- --------------- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- -----

###### 

Score of different test parameters.

  ------------- ----------- -------------------- ----------------- ------------------------ -------------------------
  Scale         0           1                    2                 3                        4
                                                                                            
  Chewability   Very poor   Poor                 Passable          Good                     Very good
  Bitterness    Bitter      Moderate to bitter   Slightly bitter   Tasteless/taste masked   Excellent taste masking
  Softness      Very hard   Hard                 Passable          Soft                     Very soft
  ------------- ----------- -------------------- ----------------- ------------------------ -------------------------

###### 

Flow properties of gum base and Drug:Excipients (D:E) mixture.

  --------------------------- -------------- -------------------------------------------------
  Flow properties             Serial no      Average values[a](#tblfn1){ref-type="table-fn"}
                                             
  Bulk density (gm/mL)        Gum base       0.66 ± 0.06
  D:E mixture                 0.67 ± 0.025   
  Tapped density (gm/mL)      Gum base       0.73 ± 0.07
  D:E mixture                 0.65 ± 0.051   
  Hausner's ratio             Gum base       1.09 ± 0.011
                              D:E mixture    1.10 ± 0.02
  Compressibility index (%)   Gum base       9.2 ± 0.72
  D:E mixture                 9.46 ± 0.17    
  Angle of repose (*θ*)       Gum base       30.70 ± 1.02
  D:E mixture                 29.49 ± 2.41   
  --------------------------- -------------- -------------------------------------------------

Data are shown as average of *n* = 3 ± SD.

###### 

Results of post-compression study of optimized MCG (M46).

  Parameters                                                Average values
  --------------------------------------------------------- ----------------
  Weight variation[a](#tblfn2){ref-type="table-fn"}         1.004 ± 0.004
  Diameter[b](#tblfn3){ref-type="table-fn"} (cm^2^)         12.48 ± 0.030
  Thickness[b](#tblfn3){ref-type="table-fn"} (mm)           6.671 ± 0.009
  Hardness[c](#tblfn4){ref-type="table-fn"} (kg/cm^2^)      2.666 ± 0.577
  Friability[b](#tblfn3){ref-type="table-fn"} (%)           0.196 ± 0.099
  Content uniformity[b](#tblfn3){ref-type="table-fn"} (%)   98.25 ± 8.404
  Loss on drying[c](#tblfn4){ref-type="table-fn"} (%)       0.40 ± 0.005

Data are shown as average of *n* = 20 ± SD.

Data are shown as average of *n* = 10 ± SD.

Data are shown as average of *n* = 6 ± SD.

###### 

Average score for four different qualities of optimized MCG (M46).

  ------------------------------------------------ -------------- --------------- -------------- ---------------------- -------------- -------------- ------------- -------------
  Parameter                                        Taste          Consistency     Softness       Flavour lasting time                                               
  Batches[a](#tblfn5){ref-type="table-fn"}         a              b               a              b                      a              b              a             b
                                                                                                                                                                    
  Average score[b](#tblfn6){ref-type="table-fn"}   3.66 ± 0.516   0.833 ± 0.752   3.16 ± 0.751   1.83 ± 0.75            3.33 ± 0.816   0.83 ± 0.752   3.5 ± 0.547   1.83 ± 1.47
  ------------------------------------------------ -------------- --------------- -------------- ---------------------- -------------- -------------- ------------- -------------

Where "a" is batch M45 and "b" is batch M4.

Data are shown as average of *n* = 6 ± SD.

###### 

Applied paired *t*-test for optimized MCG (M46) quality evaluation.

  ---------------------- ---------- ----------
  MCG quality            *t*~cal~   *t*~tab~
                                    
  Taste                  9.219      2.015
  Consistency            3.162      2.015
  Softness               7.319      2.015
  Flavour lasting time   2.5        2.015
  ---------------------- ---------- ----------

###### 

Peak load of optimized batch (M46) by texture analysis.

  ------------ ------------ ------------------- ---------------- -----------------------------------------------
  Serial no.   Probe (mm)   Compression cycle   Peak load (gm)   Average[a](#tblfn7){ref-type="table-fn"} (gm)
                                                                 
  1            4            1                   12,248           11,062 ± 1225.6
  2            4            1                   9847             
  3            4            1                   11,043           
  ------------ ------------ ------------------- ---------------- -----------------------------------------------

Data are shown as average of *n* = 3 ± SD.

###### 

*In-vivo* drug release in six healthy volunteers.

  ------------ ---------------- -------------------------------------------------- --------------- --------------- --------------- --------------- ----------------
  Serial no.   Time (minutes)   \% Drug release[a](#tblfn8){ref-type="table-fn"}                                                                   
                                Volunteer A                                        Volunteer B     Volunteer C     Volunteer D     Volunteer E     Volunteer F
                                                                                                                                                   
  1            0                0                                                  0               0               0               0               0
  2            0.5              65.76 ± 0.885                                      65.72 ± 3.500   68.90 ± 3.059   65.73 ± 0.689   64.67 ± 1.271   65.01 ± 2.259
  3            1                75.48 ± 0.413                                      71.71 ± 2.63    76.56 ± 2.121   72.71 ± 1.574   72.71 ± 1.574   72.59 ± 2.1452
  4            2                81.81 ± 2.390                                      83.25 ± 2.95    82.45 ± 2.492   80.35 ± 0.560   79.63 ± 2.283   77.86 ± 2.888
  5            5                94.37 ± 1.414                                      94.80 ± 1.013   93.10 ± 3.103   88.44 ± 2.318   87.11 ± 2.938   86.84 ± 1.550
  6            10               96.03 ± 0.915                                      96.20 ± 0.679   95.23 ± 1.389   93.09 ± 0.536   92.55 ± 2.117   90.09 ± 1.254
  7            15               97.14 ± 0.122                                      97.42 ± 0.805   96.84 ± 0.921   97.72 ± 1.011   96.95 ± 1.211   96.82 ± 1.345
  ------------ ---------------- -------------------------------------------------- --------------- --------------- --------------- --------------- ----------------

Data are shown as average of *n* = 6 ± SD.
